Your browser doesn't support javascript.
loading
Exploring the Mechanism of Shen Qi Gui Oral Liquid against Chemotherapy-Induced Myelosuppression in Cancer Patients Based on Network Pharmacology and Molecular Docking.
Wan, Feng; Zheng, Qiao; Zhou, Tiecheng; Zhou, Hang; Peng, Fu; Yao, Dejiao; Peng, Cheng.
Afiliación
  • Wan F; State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, No.1166, Liutai Avenue, Wenjiang District, Chengdu, Sichuan Province, 611137, China.
  • Zheng Q; Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, No.39, Shierqiao Road, Jinniu District, Chengdu, Sichuan Province, 610075, China.
  • Zhou T; Department of Oncology, Sichuan Integrative Medicine Hospital.
  • Zhou H; School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine.
  • Peng F; West China School of Pharmacy, Sichuan University, No. 17, Section 3, Southern Renmin Rd., Chengdu, Sichuan Province, 610041, China.
  • Yao D; Hospital of Chengdu University of Traditional Chinese Medicine Department of Oncology Chengdu China.
  • Peng C; State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, No.1166, Liutai Avenue, Wenjiang District, Chengdu, Sichuan Province, 611137, China.
Comb Chem High Throughput Screen ; 2024 Jul 09.
Article en En | MEDLINE | ID: mdl-38984575
ABSTRACT

BACKGROUND:

Shen Qi Gui oral liquid (SQG) may be beneficial for chemotherapyinduced myelosuppression (CIM). However, the underlying mechanism of CIM treated with SQG is still lacking.

METHODS:

A total of 27 blood samples from cancer patients were selected to perform RNA-seq to obtain the Differentially Expressed Genes (DEGs). Then, the active components and target genes of SQG were acquired. Next, the drug targets and DEGs were intersected to obtain the intersection genes, followed by functional enrichment analysis and construction of a drug-compoundgene- disease network. Subsequently, core genes were selected. Then, immune cell infiltration, molecular docking, pharmacokinetic and toxicity prediction, and RT-qPCR were performed.

RESULTS:

A total of 1,341 DEGs, 51 active compounds, and 264 target genes were identified. Then, 30 intersection genes were acquired. Next, a drug-compound-gene-disease network was constructed, and 7 core genes were acquired. Immune infiltration analysis exhibited that only T follicular helper cells were significantly increased in the CIM group, which was significantly negatively correlated with MAPK1, MAPK14, MCL1, PTEN, and PTGS2. The luteolin, quercetin, and beta-sitosterol showed better affinity with core genes. Luteolin and quercetin, which satisfied Lipinski's rule of five, were likely absorbed by the gastrointestinal system. Toxicity predictions showed that neither luteolin nor quercetin exhibited carcinogenicity or hepatotoxicity.

CONCLUSION:

PTEN, PTGS2, CCL2, FOS, MCL1, MAPK1, and MAPK14 were identified as the core genes in CIM patients, which were involved in the MAPK and PI3K-Akt signaling pathways. Luteolin and quercetin may be the promising drugs against CIM.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Comb Chem High Throughput Screen Asunto de la revista: BIOLOGIA MOLECULAR / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Emiratos Árabes Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Comb Chem High Throughput Screen Asunto de la revista: BIOLOGIA MOLECULAR / QUIMICA Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Emiratos Árabes Unidos